You are here: Industry Insights > Spinraza

News List

NICE expands access for SMA drug Spinraza pharmatimes
May 07, 2021
The UK’s National Institute for Health and Care Excellence (NICE) has extended the clinical eligibility criteria for Biogen’s spinal muscular atrophy (SMA) drug Spinraza following a review of data collected as part of a managed access agreement (MAA).
Biogen to study Spinraza in combination with $2-mn Novartis drug expresspharma
July 22, 2020
The one-a-day oral drug is viewed as a potential a rival to Spinraza, which is administered every four months via spinal infusion.
Biogen secures extended access agreement for Spinraza pharmaceutical-technology
July 08, 2019
The UK’s National Health Service (NHS) has extended a managed access agreement (MAA) that covers the funding of Biogen’s spinal muscular atrophy (SMA) medication Spinraza (nusinersen).
With 'remarkable' data, Biogen's Spinraza sharpens its case against Novartis gene therapy fiercepharma
July 04, 2019
Biogen credited spinal muscular atrophy (SMA) drug Spinraza as its main growth driver last year, and the company aims to keep it that way—even in the face of new competition from Novartis gene therapy Zolgensma.
Biogen's Spinraza gets a boost from NICE as competitors loom fiercepharma
May 16, 2019
As analysts speculate about the future of Biogen’s pricey spinal muscular atrophy (SMA) treatment Spinraza, the company is hoping it can corner the market before competitors take the field.
NHS England agree to pay for Biogen's $750,000 a year SMA treatment Spinraza pharmafile
May 16, 2019
NHS England has agreed to pay an undisclosed price for Biogen’s spinal muscle atrophy (SMA) treatment Spinraza.
Biogen's Spinraza gets a boost from NICE as competitors loom fiercepharma
May 16, 2019
As analysts speculate about the future of Biogen’s pricey spinal muscular atrophy (SMA) treatment Spinraza, the company is hoping it can corner the market before competitors take the field.
Gene therapy medication provides improvements in severe SMA europeanpharmaceuticalreview
April 26, 2019
Spinraza, the gene therapy medication, also provides significant improvements in cases with the next most severe form of the spinal muscular atrophy…
Biogen posts 20-percent increase in first-quarter profit, as Spinraza sales jump firstwordpharma
April 25, 2019
Biogen delivered strong financial results in the first quarter driven by the solid operational performance of our [multiple sclerosis], [spinal muscular atrophy] and biosimilars franchises ...
Late-stage pipeline drugs could compete with only treatment for SMA europeanpharmaceuticalreview
April 10, 2019
A number of drugs currently in their late stages in the development process could see competition for nusinersen, the only current SMA treatment, rise…

Previous page 1 2 Next page